4.6 Review

Human coronaviruses and therapeutic drug discovery

期刊

INFECTIOUS DISEASES OF POVERTY
卷 10, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s40249-021-00812-9

关键词

Human coronavirus; Drug discovery; Drug development; SARS-CoV-2

资金

  1. Major Science and Technology Program of Hainan Province [ZDKJ202003]
  2. National Natural Science Foundation of China [81572023, 81371836]
  3. Guangdong Natural Science Foundation [2019A1515011541]
  4. Science and Technology Planning Project of Guangdong Province [2019B030316025]
  5. National Parasitic Resources Center of China [NPRC-2019-194-30]
  6. Open Foundation of Key Laboratory of Tropical Translational Medicine of the Ministry of Education, Hainan Medical University [2020TTM007]
  7. 111 Project [B12003]
  8. Teaching Reform Project of Guangdong Province [2017001]

向作者/读者索取更多资源

This review provides an overview of drug development against HCoVs, particularly SARS-CoV-2, highlighting advancements in antiviral drugs, drugs targeting the host's immune response, and plant-derived drugs. Clinical trials targeting SARS-CoV-2 are also discussed. Efforts are being made to study the efficacy and safety of potential drugs to better control the COVID-19 pandemic.
Background: Coronaviruses (CoVs) are distributed worldwide and have various susceptible hosts; CoVs infecting humans are called human coronaviruses (HCoVs). Although HCoV-specific drugs are still lacking, many potent targets for drug discovery are being explored, and many vigorously designed clinical trials are being carried out in an orderly manner. The aim of this review was to gain a comprehensive understanding of the current status of drug development against HCoVs, particularly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Main text: A scoping review was conducted by electronically searching research studies, reviews, and clinical trials in PubMed and the CNKI. Studies on HCoVs and therapeutic drug discovery published between January 2000 and October 2020 and in English or Chinese were included, and the information was summarized. Of the 3248 studies identified, 159 publication were finally included. Advances in drug development against HCoV, especially SARS-CoV-2, are summarized under three categories: antiviral drugs aimed at inhibiting the HCoV proliferation process, drugs acting on the host's immune system, and drugs derived from plants with potent activity. Furthermore, clinical trials of drugs targeting SARS-CoV-2 are summarized. Conclusions: During the spread of COVID-19 outbreak, great efforts have been made in therapeutic drug discovery against the virus, although the pharmacological effects and adverse reactions of some drugs under study are still unclear. However, well-designed high-quality studies are needed to further study the effectiveness and safety of these potential drugs so as to provide valid recommendations for better control of the COVID-19 pandemic.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据